

Research

Open Access

Utility of Cardiac Magnetic Resonance to assess association between admission hyperglycemia and myocardial damage in patients with reperfused ST-Segment Elevation Myocardial Infarction

Alexandre Cochet*¹, Marianne Zeller², Alain Lalande¹, Isabelle L'Huillier³, Paul M Walker¹, Claude Touzery¹, Bruno Verges⁴, Jean-Eric Wolf³, François Brunotte¹ and Yves Cottin³

Address: ¹Unité d'IRM, CHU Hôpital d'enfants, Boulevard du Maréchal de Lattre de Tassigny, 21034 Dijon, France, ²Institut Fédératif de Recherche Santé STIC, Université de Bourgogne, France, ³Département de Cardiologie, CHU Bocage, Boulevard du Maréchal de Lattre de Tassigny, 21034 Dijon, France and ⁴Département d'Endocrinologie, CHU Bocage, Boulevard du Maréchal de Lattre de Tassigny, 21034 Dijon, France

Email: Alexandre Cochet* - alexandre.cochet@neuf.fr; Marianne Zeller - alexandre.cochet1@neuf.fr; Alain Lalande - alexandre.cochet2@neuf.fr; Isabelle L'Huillier - alexandre.cochet3@neuf.fr; Paul M Walker - alexandre.cochet4@neuf.fr; Claude Touzery - alexandre.cochet5@neuf.fr; Bruno Verges - alexandre.cochet6@neuf.fr; Jean-Eric Wolf - alexandre.cochet7@neuf.fr; François Brunotte - alexandre.cochet8@neuf.fr; Yves Cottin - alexandre.cochet9@neuf.fr

* Corresponding author

Published: 15 January 2008

Received: 4 December 2007

Journal of Cardiovascular Magnetic Resonance 2008, **10**:2 doi:10.1186/1532-429X-10-2

Accepted: 15 January 2008

This article is available from: <http://www.jcmr-online.com/content/10/1/2>

© 2008 Cochet et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Aims: to investigate the association between admission hyperglycemia and myocardial damage in patients with ST-segment elevation myocardial infarction (STEMI) using Cardiac Magnetic Resonance (CMR).

Methods: We analyzed 113 patients with STEMI treated with successful primary percutaneous coronary intervention. Admission hyperglycemia was defined as a glucose level ≥ 7.8 mmol/l. Contrast-enhanced CMR was performed between 3 and 7 days after reperfusion to evaluate left ventricular function and perfusion data after injection of gadolinium-DTPA. First-pass images (FP), providing assessment of microvascular obstruction and Late Gadolinium Enhanced images (DE), reflecting the extent of infarction, were investigated and the extent of transmural tissue damage was determined by visual scores.

Results: Patients with a supramedian FP and DE scores more frequently had left anterior descending culprit artery ($p = 0.02$ and <0.001), multivessel disease ($p = 0.02$ for both) and hyperglycemia ($p < 0.001$). Moreover, they were characterized by higher levels of HbA_{1c} ($p = 0.01$ and 0.04), peak plasma Creatine Kinase ($p < 0.001$), left ventricular end-systolic volume ($p = 0.005$ and <0.001), and lower left ventricular ejection fraction ($p = 0.001$ and <0.001).

In a multivariate model, admission hyperglycemia remains independently associated with increased FP and DE scores.

Conclusion: Our results show the existence of a strong relationship between glucose metabolism impairment and myocardial damage in patients with STEMI. Further studies are needed to show if aggressive glucose control improves myocardial perfusion, which could be assessed using CMR.

Introduction

Admission hyperglycemia is associated with increased short and long term risk of death in patients with ST-segment elevation myocardial infarction (STEMI), independently of the presence of Diabetes Mellitus [1-3]; this increased mortality might be explained by a higher incidence of congestive heart failure and cardiogenic shock [2,4]. Moreover, a recent study suggested an association between admission hyperglycemia and the no-reflow phenomenon as assessed by myocardial contrast echocardiography [5]. In contrast, the association between hyperglycemia and the extent of myocardial infarct size is less clear [6-8].

Cardiac Magnetic Resonance (CMR) with a gadolinium-based contrast agent is considered to accurately assess myocardial perfusion and function abnormalities after STEMI. First pass (FP) perfusion provides a valuable assessment of the extent of microvascular obstruction (MO) [9], and Late Gadolinium Enhancement (DE) reflects the extent of myocardial infarction [10,11]. However, no data are available on the relationship between admission glycemia and CMR data in the setting of STEMI.

The objective of the present study was to investigate the relationship between blood glucose levels taken on admission and myocardial perfusion parameters assessed by contrast-enhanced CMR in patients after reperfusion of an acute STEMI.

Methods

Study population

One hundred and thirty one consecutive patients presenting with a first acute STEMI and who underwent primary percutaneous coronary intervention (PCI, angiography and/or stenting) for arteries exhibiting Thrombolysis In Myocardial Infarction (TIMI) flow grade < 3, within 24 hours after symptom onset, were included in the study. Patients with TIMI flow <3 on the culprit lesion after PCI, or who were hemodynamically unstable or with a contraindication for CMR were excluded from the study. The diagnosis of STEMI was based on prolonged chest pain, ST-segment elevation ≥ 2 mm in at least two contiguous electrocardiographic (ECG) leads, and a more than three fold increase in serum creatine kinase (CK) levels [12,13].

Fourteen patients with a TIMI flow <3 post-PCI and 4 patients with contraindications for CMR were excluded from the study

Therefore, the study population consisted of 113 patients (91 men and 22 women, mean age 57 ± 14 years).

All participants gave written consent before entering the study, in accordance with a protocol approved by the institutional ethics committee.

Data Collection

Demographic data, age, gender, Body Mass Index (weight/height², kg/m²), clinical history of hypertension, diabetes mellitus, hypercholesterolemia, smoking, previous PCI and/or Coronary Artery Bypass Graft and peripheral arterial disease were recorded as were on-admission clinical data (Killip class, ECG and hemodynamic parameters). Heart failure was defined by Killip class > 1. Location of MI was determined according to ECG, coronary angiographic and CMR data; no discordance was observed between the 3 methods. Current treatment before hospitalization was also recorded. Blood samples were taken at admission to measure glucose and C-Reactive Protein levels. HbA_{1c}, HDL-Cholesterol, LDL-Cholesterol and triglyceride levels were assessed from fasting blood sample taken on the first morning after admission. Peak plasma levels of Creatine Kinase (CK) were also evaluated and dichotomized at ten times the upper normal limit for more clinical relevance. Baseline serum creatinine clearance was also evaluated by the Cockcroft-Gault formula [14].

CMR protocol

Patients were examined 3 to 7 days after STEMI. Contrast-enhanced CMR was performed on a 1.5 T whole-body MR imager (Magnetom Vision, Siemens GmbH, Erlangen, Germany), using a phased array body coil. Left ventricular (LV) long-axis scout images were obtained to determine the orientation of the LV short axis imaging planes.

For LV function evaluation, cine-CMR was performed using a breath-hold ECG-gated gradient echo sequence (FLASH 2D), with the following acquisition parameters: repetition time (TR) 9 ms, echo time (TE) 4.4 ms, pulse flip angle (α) 15°, 9 lines per segment, field of view (FOV) of 350 to 400 mm. The acquisition matrix varied from 108 × 256, (12 cardiac cycles), to 144 × 256, (16 cardiac cycles), depending on the ability of patient to hold his breath. A series of short-axis slices (thickness of 5 mm with a gap between slices of 10 mm) was defined from the base of the heart to the apex [15]. The image of the heart was taken into account at end-systole and end-diastole times. A temporal resolution of 50 ms was obtained with the "view-sharing" technique [16].

For LV perfusion evaluation, a first-pass ECG-gated gradient echo sequence was performed (T1-weighted turbo-FLASH sequence) after injection of a bolus of gadolinium-diethylenetriamine pentaacetic acid (Magnevist, Schering-AG, Berlin, Germany) into a brachial vein at 0.1 mmol/Kg; the acquisition parameters were as follows: inversion time (TI) 400 ms, TR 3.5 ms, TE 1.7 ms, FOV 350 to 400

mm, and acquisition matrix 96×128 , interpolated to 256×256 . A time delay buffer at the end of the sequence was adjusted in order to acquire one image every two cardiac cycles. Three to five short-axis slices were obtained from the base of the heart to the apex, with the same plane as for the functional study (thickness of 12 mm with a gap between slices of 3 mm) (Figure 1) [17].

Ten minutes after bolus injection, delayed images were acquired using a segmented T1-weighted inversion-recovery turboFLASH sequence [18], with the following parameters: TR = 2 cardiac cycles; TE = 3.4 ms; $\alpha = 25^\circ$; FOV = 350 mm; acquisition matrix = 165×256 , interpolated to 256×256 , with a variable TI adjusted for each patient studied in order to optimize the nulling of normal myocardium [19]. This time delay was usually about 250 ms (Figure 2). The image planes were the same as for functional and first-pass studies (thickness of 8 mm with a gap between slices of 7 mm).

CMR data analysis

A 17-segment model was used for the data analysis of perfusion studies [20]. Left ventricular end-diastolic volume (EDV) and end-systolic volume (ESV) were calculated from short-axis views using a method previously described [15]. Left ventricular ejection fraction (LVEF) was calculated with the following formula: $LVEF = (EDV - ESV)/EDV$.




Figure 1
Short-axis gradient-echo CMR images at basal (a), mid-ventricular (b, c) and distal (d) levels, during first pass of a bolus of gadolinium-DTPA, showing a localized microvascular obstruction in the antero-septal territory.




Figure 2
Short axis basal (a), mid-ventricular (b, c) and distal (d) segmented Inversion Recovery gradient echo MR images 10 minutes after bolus injection of Gadolinium-DTPA, showing a large region of myocardial damage (hyperenhancement surrounding region of persistent hypoenhancement in the antero-septal territory (same patient than Figure 1)).

For each patient, perfusion data were analysed and visual scores were independently attributed by two expert investigators blinded to clinical data. These scores were given according to the signal intensity observed on early images (First-pass images: FP) for 16 segments (the apical segment was not evaluated on early images, because no long axis slice was obtained), and late images (delayed enhanced images: DE, 10 minutes after injection) for each of the 17 segments (vertical and horizontal long-axis slices made it possible to evaluate the apical segment). Early regional hypoenhancement and late regional hyperenhancement were scored with a scheme based on the transmural extent of contrast enhanced tissue within each segment (0 = no hypo or hyperenhancement; 1 = 1–25% hypo or hyperenhancement; 2 = 26–50% hypo or hyperenhancement; 3 = 51–75 hypo or hyperenhancement; 4 = 76–100% hypo or hyperenhancement). The two scores, FP, which reflects microvascular obstruction and DE, which reflects myocardial infarct size, were determined by calculating the sum of the scores of all of the segments (16 for FP, 17 for DE). Thus, the scores ranged from 0 to 64 for FP, and from 0 to 68 for DE images [21]. Some areas, known as no-reflow zones, have major micro-vascular damage and are characterized by a persistent hypoenhanced area even on delayed images [22]. Thus, the observers were requested to include the no-reflow zones in the extent of infarction (DE score).

Concordance between expert investigators was satisfactory (interobserver variability <5%). In cases of disagreement, the final decision was taken by consensus.

Statistical analysis

Continuous data were expressed as median (25th percentile – 75th percentile) and dichotomous data as numbers (percentages).

Patients were categorized according to the median values of FP and DE scores. Comparison between groups was made using the Student t test or the Mann-Whitney test for continuous variables and the Chi square test for discrete variables. Admission glycemia was dichotomized according to presence of hyperglycemia. Hyperglycemia was defined as glucose levels on admission of ≥ 7.8 mmol/l (140 mg/dl), in accordance with the guidelines of the American Diabetes Association [23]. Patients were also categorized according to the presence of hyperglycemia at admission, with regard to CMR data.

Multivariate logistic regression analysis was performed to test for independent predictors of high perfusion scores (>

median value). The following variables, with a p value of less than 0.1 on univariate analysis were included in the models: left anterior descending culprit artery, multivessel disease, TIMI 0 or 1 before PCI, hyperglycemia, HbA_{1c}, peak CK level, ESV and LVEF. Moreover, age and sex were also included in the models.

The Spearman rank test was performed to analyse the relationship between glycemia and perfusion scores.

All the tests were two-sided and a p value <0.05 was considered as significant.

Statistical analysis was performed with Sigstatat version 2.3 (Statistical Software, SPSS Inc, USA).

Results

Determinants of microvascular obstruction (FP score)

Characteristics of the patients according to the median value of the FP score are shown in Tables 1 and 2. Patients with high FP score (>median) more frequently had left anterior descending culprit artery (p = 0.02), multivessel disease (p = 0.02) and hyperglycemia (p < 0.001) than

Table 1: Risk factors, biological data and medications according to FP and DE scores: n (%) or median (25th and 75th percentile)

	FP score \leq median (n = 57)	FP score > median (n = 56)	p	DE score \leq median (n = 57)	DE score > median (n = 56)	p
Risk factors						
Age (years)	56 (48–69)	56 (49–68)	0.66	56 (51–68)	57 (48–68)	0.98
Male	43 (75)	48 (86)	0.25	44 (77)	47 (84)	0.51
BMI (kg/m ²)	25 (24–28)	26 (24–28)	0.35	25 (24–29)	25 (24–28)	0.54
Hypertension	25 (44)	16 (29)	0.14	22 (39)	19 (34)	0.75
Diabetes	5 (9)	7 (12)	0.74	6 (11)	6 (11)	0.79
Hypercholesterolemia	19 (33)	23 (41)	0.51	23 (40)	19 (34)	0.61
Smoking	23 (40)	29 (52)	0.30	22 (39)	30 (54)	0.42
Previous PCI or CABG	2 (4)	2 (4)	1.00	3 (5)	1 (2)	0.62
Peripheral arterial disease	2 (4)	2 (4)	1.00	2 (4)	2 (4)	1.00
Biological data						
Hyperglycemia (≥ 7.8 mmol/l)	17 (30)	35 (63)	<0.001	16 (28)	36 (64)	<0.001
Glycemia (mmol/l)	7.0 (6.1–8.4)	8.4 (6.9–9.7)	0.001	6.9 (5.9–8.2)	8.4 (7.0–9.6)	<0.001
HbA _{1c} (%)	5.4 (5.2–5.7)	5.7 (5.4–6.3)	0.01	5.5 (5.2–5.7)	5.7 (5.4–6.3)	0.04
Peak CK >10 fold UNL	21 (37)	45 (80)	<0.001	17 (30)	49 (88)	<0.001
CRP (mg/l)	2.2 (1.7–10.0)	4.6 (2.0–11.0)	0.48	2.5 (2.0–11.0)	4.7 (2.0–9.0)	0.81
Creatinine clearance (ml/mn)	87 (73–116)	92 (75–111)	0.48	92 (74–117)	88 (72–111)	0.77
HDL-Cholesterol (mmol/l)	1.04 (0.91–1.33)	1.17 (0.96–1.41)	0.15	1.08 (0.91–1.33)	1.17 (0.94–1.34)	0.50
LDL-Cholesterol (mmol/l)	2.99 (2.49–3.73)	3.01 (2.49–3.90)	0.74	2.93 (2.47–3.79)	3.19 (2.56–3.84)	0.54
Triglyceride (mmol/l)	1.42 (0.92–2.5)	1.29 (0.97–1.73)	0.22	1.45 (1.01–2.4)	1.26 (0.90–1.79)	0.08
Current treatment						
Statin	6 (11)	8 (14)	0.75	6 (11)	8 (14)	0.75
Insulin	1 (2)	0 (0)	0.99	1 (2)	0 (0)	0.99
ACE inhibitor	6 (11)	3 (5)	0.51	3 (5)	6 (11)	0.47
Beta Blocker	10 (18)	6 (11)	0.44	9 (16)	7 (13)	0.82
Oral antidiabetic	2 (4)	4 (7)	0.66	2 (4)	4 (7)	0.66
Acute medications						
Gp IIb/IIIa receptor blocker	30 (53)	23 (41)	0.30	24 (42)	29 (52)	0.40
Antiplatelet	48 (84)	52 (93)	0.25	48 (84)	52 (93)	0.25

ACE = Angiotensin-Converting Enzyme; BMI = Body Mass Index; CABG = Coronary Artery Bypass Graft; CK = Creatine Kinase; CRP = C-Reactive Protein; PCI = Percutaneous Coronary Intervention; SBP = Systolic Blood Pressure; UNL = Upper Normal Limit.

Table 2: Clinical data, coronary angiographic data, and CMR data according to FP and DE scores: n (%) or median (25th and 75th percentile)

	FP score ≤ median (n = 57)	FP score > median (n = 56)	p	DE score ≤ median (n = 57)	DE score > median (n = 56)	p
Clinical data						
Heart failure	8 (14)	3 (5)	0.22	6 (11)	5 (9)	0.98
Heart rate (beats/min)	75 (65–84)	75 (61–80)	0.49	76 (64–84)	75 (62–80)	0.39
Blood pressure						
SBP (mm/Hg)	140 (120–155)	140 (120–160)	0.84	140 (120–153)	140 (120–160)	0.87
DBP (mm/Hg)	84 (70–95)	80 (70–99)	0.85	84 (70–94)	80 (70–100)	0.90
Heart rate-SBP product	10477 (8100–12775)	9660 (7874–12600)	0.29	10077 (7800–12915)	9975 (8000–12464)	0.29
Coronary angiographic data						
Culprit artery						
Left anterior descending	20 (35)	33 (59)	0.02	16 (28)	37 (66)	<0.001
Left circumflex	7 (12)	5 (9)	0.79	9 (16)	3 (5)	0.41
Right coronary	30 (53)	18 (32)	0.04	32 (56)	16 (29)	0.006
Location of lesion (% proximal/mid/distal)	30/58/12	36/55/9	0.79	26/64/10	40/49/11	0.28
TIMI 0/I pre-PCI in culprit artery	35 (61)	42 (75)	0.18	31 (54)	46 (82)	0.003
Multivessel disease	19 (33)	30 (54)	0.02	19 (33)	30 (54)	0.02
Stenting	56 (98)	55 (98)	0.48	55 (96)	56 (100)	0.48
Stent length > 15 mm	17 (30)	19 (34)	0.79	18 (32)	18 (32)	0.89
Stent width > 3 mm	15 (26)	13 (23)	0.87	15 (26)	13 (23)	0.87
IABP use	1 (2)	2 (4)	0.99	0 (0)	3 (5)	0.24
Time to reperfusion (min)	205 (145–399)	187 (130–265)	0.19	189 (134–339)	190 (130–265)	0.43
CMR data						
FP score	2 (0–4)	13 (9–19)		2 (0–6)	11 (7–15)	<0.001
DE score	10 (4–15)	20 (16–28)	<0.001	9 (4–12)	23 (18–29)	
LVEF (%)	54 (48–59)	46 (38–56)	0.001	55 (48–60)	44 (37–55)	<0.001
EDV (ml)	132 (117–165)	154 (130–177)	0.06	132 (117–160)	155 (130–178)	0.01
ESV (ml)	66 (50–77)	77 (59–100)	0.005	57 (48–74)	83 (63–103)	<0.001

DBP = Diastolic Blood Pressure; DE = Delayed-Enhancement; EDV = End Diastolic Volume; ESV = End Systolic Volume; FP = First Pass; IABP = Intra-Aortic Balloon Pumping; LVEF = Left Ventricular Ejection Fraction; PCI = Percutaneous Coronary Intervention; SBP = Systolic Blood Pressure.

patients with low FP score. Moreover, the level of HbA_{1c} (p = 0.01), peak CK (p < 0.001), ESV (p = 0.005) and DE score (p < 0.001) were higher in patients with a high FP score. In contrast, LVEF was lower in the group with a high FP score (p < 0.001).

Multivariate analysis showed that peak CK (odds ratio [OR] 4.2; 95% confidence interval [CI] 1.6–11.1; p = 0.004) and hyperglycemia (OR 3.8; 95% CI 1.4–9.9; p = 0.007) were independent predictors of high (supra-median) FP scores. However, when DE score was included in the multivariate model, only DE remained an independent predictor of high FP score (Table 3).

Determinants of myocardial infarct size (DE score)

Patients with high DE scores (> median) had increased risk of left anterior descending culprit artery (p < 0.001), TIMI 0 or 1 before PCI in culprit artery (p = 0.003) and hyperglycemia (p = <0.001) (Tables 1 and 2). HbA_{1c} (p = 0.04), peak CK (p < 0.001), EDV (p = 0.01), ESV (p < 0.001) and FP score (p < 0.001) were also increased in this group. In contrast, LVEF (p < 0.001) was significantly decreased in patients with higher DE scores. Multivariate analysis showed that hyperglycemia (OR 10.4; 95% CI 2.8–40.3; p < 0.001), left anterior descending culprit artery (OR 6.6; 95% CI 1.7–25.4; p = 0.006) and peak CK (OR 19.2; 95% CI 4.8–76.7; p < 0.001) were independent predictors of high DE scores. When FP score was included

Table 3: CMR data according to admission hyperglycemia. All values are expressed as median (25th – 75th percentile)

	Without hyperglycemia (n = 61)	With hyperglycemia (n = 52)	p
FP score	4 (0–8)	10 (5–16)	<0.001
DE score	11 (6–19)	18 (14–26)	<0.001
LVEF (%)	53 (43–59)	50 (43–56)	0.38
EDV (ml)	148 (125–170)	142 (117–173)	0.23
ESV (ml)	69 (55–84)	68 (51–95)	0.85

DE = Delayed-Enhancement; EDV = End Diastolic Volume; ESV = End Systolic Volume; FP = First Pass; LVEF = Left Ventricular Ejection Fraction.

in the multivariate model, hyperglycemia, left anterior descending culprit artery, peak CK, and FP score remained independent predictors of high DE score (Table 3).

Hyperglycemia and perfusion scores

Spearman rank correlation analysis showed a positive relationship between admission glycemia and perfusion scores ($r = +0.34$ and $p < 0.001$ for the FP score; $r = +0.32$ and $p < 0.001$ for the DE score). Categorization of patients according to the presence of hyperglycemia showed that FP (4 [0–8] vs 10 [5–16]; $p < 0.001$) and DE scores (11 [6–19] vs 18 [14–26]; $p < 0.001$) were higher in patients with hyperglycemia. In contrast, there was no difference between the 2 groups for LVEF (53 [43–59] vs 50 [43–56] %; $p = 0.38$), EDV (148 [125–170] vs 142 [117–173] ml; $p = 0.23$) and ESV (69 [55–84] vs 68 [51–95] ml; $p = 0.85$).

Discussion

The major findings of the present study are that admission hyperglycemia, in the setting of an acute STEMI, is associated with the extent of MO as assessed by CMR. Hyperglycemia was also an independent predictor of myocardial infarct size.

Hyperglycemia and microvascular obstruction

First-pass hypoenhancement is recognized as closely defining the extent of MO [24], and is strongly associated with worse outcome after STEMI [25–27]. MO is a major factor involved in the development of the angiographic "no-reflow" phenomenon, and limits the benefits of reperfusion [28]. MO may result from leukocyte entrapment in capillaries [29], and from distal microembolization of platelets which aggregate and adhere to capillary walls following plaque rupture [30].

In the present study, admission hyperglycemia was a predictive factor for the extent of MO, as assessed by the FP score. To the best of our knowledge, this is the first study to analyse the relationship between acute hyperglycemia and MO assessed by CMR, after successful reperfusion. Nevertheless, these findings are in agreement with those of Iwakura et al, who investigated the impact of admission hyperglycemia and the no-reflow phenomenon, assessed by intracoronary myocardial contrast echocardiography immediately after successful reperfusion [5]. They found that hyperglycemia was the strongest predictive factor for no-reflow.

The potential mechanisms involved in this relationship have yet to be elucidated. Even so, acute hyperglycemia is associated with increased platelet activation and fibrinolysis [31], as well as plugging of capillaries by leukocytes [32]. Acute hyperglycemia may also attenuate endothelium dependent vasodilatation, and reduce collateral

blood flow to the area at risk [33]. Moreover, hyperglycemia may reduce the impact of ischemic preconditioning, through the attenuation of mitochondrial adenosine triphosphate-regulated K channel activation [34]. All of these mechanisms could strongly interact to favor the development of MO. However, in our study MO was mainly related to myocardial infarct size; which could partly explain the relation observed between hyperglycemia and MO.

Hyperglycemia and myocardial infarct size

CMR, with Late Gadolinium Enhancement is widely used to define infarct size. Extra-cellular contrast-agents accumulate in the myocardium due to increased capillary permeability oedema, increased extra-cellular space and slower kinetics in infarcted regions [24,35]. One major finding of the present work was the close relationship between admission glycemia and the extent of myocardial infarction assessed by the DE score, independently of pre-existing glucose metabolism (HbA_{1c}) or markers of myocardial infarct size (peak CK value). The impact of stress hyperglycemia on the extent of myocardial necrosis is not fully understood. Acute hyperglycemia may increase the inflammatory response during STEMI, and could thus influence microvascular permeability and oedema [36]. Moreover, in a recent study, Timmer et al found that, in patients with STEMI, admission hyperglycemia was an important predictor of reduced epicardial flow in the infarct-related vessel before reperfusion therapy [37]. They also suggest that acute rather than chronic hyperglycemia is more important in predicting TIMI flow in patients after PCI.

Finally, admission hyperglycemia may not only be the cause of more severe myocardial damage, but also its consequence. Large myocardial infarcts are more likely to cause excessive secretion of catecholamine, which affect fatty acids and glucose homeostasis [38]. However, stress hyperglycemia is an imperfect marker of cardiac damage, as many other markers in addition to stress hormones contribute to glucose metabolism [2].

Study limitations

Follow-up data were not available in this study, which attenuates the impact of the study conclusion.

For evaluation of perfusion and Late Gadolinium enhancement, we did not use a real quantitative method but a semi-quantitative visual method to grade the extent of transmural myocardial damage [11,22]. However, the 17 segment model, which has gained wide acceptance in scintigraphic myocardial perfusion imaging, is both easy to obtain and reproducible. Moreover in a previous study we showed an excellent correlation and concordance

between visual grading and planimetric evaluation of myocardial enhancement [21].

The correlation between glycemia and perfusion scores, although significant, was weak. This relation was consolidated by the analysis of determinants of supramean perfusion scores (Table 1). However, the relationship between admission glycemia and FP or DE parameter needs to be demonstrated in larger study population.

Conclusion

Abnormal glucose metabolism is strongly associated with MO and the extent of myocardial infarct in successfully reperfused STEMI, as assessed by CMR. These results emphasize the interest of aggressive glucose control at the acute phase of STEMI. Moreover, CMR could play a major role in evaluating the impact of glucose control on myocardial perfusion.

Abbreviations

CK: Creatine Kinase;

CMR: Cardiac Magnetic Resonance Imaging;

DE: Delayed Contrast-Enhanced;

EDV: Left Ventricular End Diastolic Volume;

ESV: Left Ventricular End Systolic Volume;

FP: First Pass;

LVEF: Left Ventricular Ejection Fraction;

MO: Microvascular Obstruction;

PCI: Percutaneous Coronary Intervention;

STEMI: ST-Segment Elevation Myocardial Infarction;

TIMI: Thrombolysis in Myocardial Infarction.

Competing interests

The author(s) declare that they have no competing interests.

Authors' contributions

Each author have contributed significantly to the submitted work. Analysis and interpretation of data have been performed by AC, MZ, IL and CT; drafting of the manuscript by AC, MZ, YC, FB, and JEW; AL, PMW and BV have revised the manuscript for important intellectual content. All authors read and approved the final manuscript.

Acknowledgements

This work was supported by the Association de Cardiologie de Bourgogne and by grants from the University Hospital of Dijon, France. The authors are grateful for P. Bastable for his help in the preparation of the manuscript, and Dr C. Boichot for the collection of data.

References

1. Stranders I, Diamant M, van Gelder RE, Spruijt HJ, Twisk JW, Heine RJ, Visser FC: **Admission blood glucose level as risk indicator of death after myocardial infarction in patients with and without diabetes mellitus.** *Arch Intern Med* 2004, **164**:982-988.
2. Capes S, Hunt D, Malmberg K, Gerstein HC: **Stress hyperglycemia and increased risk of death after myocardial infarction in patients with or without diabetes: a systematic.** *Lancet* 2000, **355**:773-778.
3. Wahab NN, Cowden EA, Pearce NJ, Gardner MJ, Merry H, Cox JL, ICONS Investigators: **Is blood glucose an independent predictor of mortality in acute myocardial infarction in the thrombolytic era?** *J Am Coll Cardiol* 2002, **40**:1748-1754.
4. Zeller M, Cottin Y, Brindisi MC, Dentan G, Laurent Y, Janin-Manificat L, L'Huillier I, Beer JC, Touzery C, Makki H, Verges B, Wolf JE: **The RICO survey working group. Impaired fasting glucose and cardiogenic shock in patient with acute myocardial infarction.** *Eur Heart J* 2004, **25**:308-312.
5. Iwakura K, Ito H, Ikushima M, Kawano S, Okamura A, Asano K, Kuroda T, Tanaka K, Masuyama T, Hori M, Fujii K: **Association between hyperglycemia and the no reflow phenomenon in patients with acute myocardial infarction.** *J Am Coll Cardiol* 2003, **41**:1-7.
6. Marfella R, D'Amico M, Di Filippo C, Piegari E, Nappo F, Esposito K, Berrino L, Rossi F, Giugliano D: **Myocardial infarction in diabetic rats: role of hyperglycemia on infarct size and early expression of hypoxia-inducible factor 1.** *Diabetologia* 2002, **45**:1172-1181.
7. Timmer JR, van der Horst IC, Ottervanger JP, Henriques JP, Hoorntje JC, de Boer MJ, Suryapranata H, Zijlstra F: **Prognostic value of admission glucose in non-diabetic patients with myocardial infarction.** *Am Heart J* 2004, **148**:399-404.
8. Solomon SD, John St, Sutton M, Lamas GA, Plappert T, Rouleau JL, Skali H, Moye L, Braunwald E, Pfeffer MA, Survival And Ventricular Enlargement (SAVE) Investigators: **Ventricular remodeling does not accompany the development of heart failure in diabetic patients after myocardial infarction.** *Circulation* 2002, **106**:1251-1255.
9. Rochitte CE, Lima JA, Bluemke DA, Reeder SB, McVeigh ER, Furuta T, Becker LC, Melin JA: **Magnitude and time course of microvascular obstruction and tissue injury after acute myocardial infarction.** *Circulation* 1998, **98**:1006-1014.
10. Judd RM, Lugo-Olivieri CH, Arai M, Kondo T, Croisille P, Lima JA, Mohan V, Becker LC, Zerhouni EA: **Physiological basis of myocardial contrast enhancement in fast magnetic resonance images of 2-day-old reperfused canine infarcts.** *Circulation* 1995, **92**:1902-1910.
11. Choi KM, Kim RJ, Gubernikoff G, Vargas JD, Parker M, Judd RM: **Transmural extent of acute myocardial infarction predicts long-term improvement in contractile function.** *Circulation* 2001, **104**:1101-1107.
12. Alpert JS, Thygesen K, Antman E, Bassand JP: **Myocardial infarction redefined—a consensus document of The European Society of Cardiology/American Society of Cardiology Committee for the redefinition of myocardial infarction.** *J Am Coll Cardiol* 2001, **36**(3):959-969.
13. The GRACE investigators: **Rationale and design of the GRACE (Global Registry of Acute Coronary Events) Project: A multinational registry of patients hospitalized with acute coronary syndromes.** *Am Heart J* 2001, **141**:190-199.
14. Cockcroft DW, Gault MH: **Prediction of creatinine clearance from serum creatinine.** *Nephron* 1976, **16**:31-41.
15. Cottin Y, Touzery C, Guy F, Lalonde A, Ressenecourt O, Roy S, Walker PM, Louis P, Brunotte F, Wolf JE: **MR imaging of the heart after myocardial infarction: effect of increasing intersection gap on measurement of left ventricular volume, ejection fraction, and wall-thickness.** *Radiology* 1999, **213**:513-520.
16. Foo TKF, Bernstein MA, Aisen AM, Hernandez RJ, Collick BD, Bernstein T: **Improved ejection fraction and flow velocity esti-**

- mates with use of view-sharing and uniform repetition time excitation with fast cardiac techniques. *Radiology* 1995, **195**:471-478.
17. Lauerma K, Virtanen KS, Sipila LM, Hekali P, Aronen HJ: **Multislice MRI in assessment of myocardial perfusion in patients with single-vessel proximal left anterior descending coronary artery disease before and after revascularization.** *Circulation* 1997, **96**:2859-2867.
 18. Kim RJ, Fieno DS, Parrish TB, Harris K, Chen EL, Simonetti O, Bundy J, Finn JP, Klocke FJ, Judd RM: **Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function.** *Circulation* 1999, **100**:1992-2002.
 19. Simonetti O, Kim RJ, Fieno DS, Hillenbrand HB, Wu E, Bundy JM, Finn JP, Judd RM: **An improved MR Imaging technique for the visualization of myocardial infarction.** *Radiology* 2001, **218**:215-223.
 20. Cerqueira MD, Weissman NJ, Dilsizian V, Jacobs AK, Kaul S, Laskey WK, Pennell DJ, Rumberger JA, Ryan T, Verani MS: **American Heart Association Writing Group on Myocardial Segmentation and Registration for Cardiac Imaging. Standardized myocardial segmentation and nomenclature for tomographic imaging of the Heart.** *Circulation* 2002, **105**:539-542.
 21. Comte A, Lalande A, Walker PM, Cochet A, Legrand L, Cottin Y, Wolf JE, Brunotte F: **Visual estimation of the global myocardial extent of hyperenhancement on delayed contrast-enhanced MRI.** *Eur Radiol* 2004, **14**:2182-2187.
 22. Beek AM, Kuhl HP, Bondarenko O, Twisk JW, Hofman MB, van Doornik WG, Visser CA, van Rossum AC: **Delayed contrast-enhanced magnetic resonance imaging for the prediction of regional functional improvement after acute myocardial infarction.** *J Am Coll Cardiol* 2003, **42**:895-901.
 23. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: **Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus.** *Diabetes Care* 2004, **27**(Suppl 1):S5-10.
 24. Lima JAC, Judd RM, Bazille A, Schulman SP, Atalar E, Zerhouni EA: **Regional heterogeneity of human myocardial infarcts demonstrated by contrast-enhanced MRI. Potential mechanisms.** *Circulation* 1995, **92**:1117-1125.
 25. Rogers WJ, Kramer CM, Geskin G, Hu YL, Theobald TM, Vido DA, Petruolo S, Reichel N: **Early contrast-enhanced MRI predicts late functional recovery after reperfused myocardial infarction.** *Circulation* 1999, **99**:744-750.
 26. Wu KC, Zerhouni EA, Judd RM, Lugo-Olivieri CH, Barouch LA, Schulman SP, Blumenthal RS, Lima JA: **Prognostic significance of microvascular obstruction by magnetic resonance imaging in patients with acute myocardial infarction.** *Circulation* 1998, **97**:765-772.
 27. Gerber BL, Garot J, Bluemke DA, Wu KC, Lima JAC: **Accuracy of contrast-enhanced magnetic resonance imaging in predicting improvement of regional myocardial function in patients after acute myocardial infarction.** *Circulation* 2002, **106**:1083-1089.
 28. Kloner RA, Ganote CE, Jennings RB: **The "no-reflow" phenomenon after temporary coronary occlusion in the dog.** *J Clin Invest* 1974, **54**:1496-1508.
 29. Engler RL, Schmid-Schonbein GW, Pavelec RS: **Leukocyte capillary plugging in myocardial ischemia and reperfusion in dogs.** *Am J Pathol* 1983, **111**:98-111.
 30. Topol EJ, Yadav JS: **Recognition of the importance of embolization in atherosclerotic vascular disease.** *Circulation* 2000, **101**(5):R570-R580.
 31. Shechter M, Merz MB, Paul-Labrador MJ, Kaul S: **Blood glucose and platelet-dependent thrombosis in patients with coronary artery disease.** *J Am Coll Cardiol* 2000, **35**:300-307.
 32. Marfella R, Esposito K, Giunta R, Coppola G, De Angelis L, Farzati B, Paolisso G, Giugliano D: **Circulating adhesion molecules in humans: role of hyperglycemia and hyperinsulinemia.** *Circulation* 2000, **101**:2247-2251.
 33. Kersten JR, Toller WG, Tessmer JP, Pagel PS, Waltier DC: **Hyperglycemia reduces coronary collateral blood flow through a nitric oxide-mediated mechanism.** *Am J Physiol Heart Circ Physiol* 2001, **281**:H2097-2104.
 34. Kersten JR, Schemling TJ, Orth KG, Pagel PS, Waltier DC: **Acute hyperglycemia abolishes ischemic preconditioning in vivo.** *Am J Physiol Heart Circ Physiol* 1998, **275**(2 Pt 2):H721-H725.
 35. Saeed M, Wendland MF, Masui T, Higgins CB: **Reperfused myocardial infarctions on T1- and susceptibility-enhanced MRI: evidence for loss of compartmentalization of contrast media.** *Magn Reson Med* 1994, **31**:31-39.
 36. Marfella R, Siniscalchi M, Esposito K, Cacciapuoti F, Giugliano F, Labriola D, Ciotola M, Di Palo C, Misso L, Giugliano D: **Effects of stress hyperglycemia on acute myocardial infarction: role of inflammatory immune process in functional cardiac outcome.** *Diabetes Care* 2003, **26**:3129-3135.
 37. Timmer JR, Ottervanger JP, de Boer MJ, Dambrink JH, Hoorntje JC, Gosselink AT, Suryapranata H, Zijlstra F, van't Hof AW, Zwolle Myocardial Infarction Study Group: **Hyperglycemia is an important predictor of impaired coronary flow before reperfusion therapy in ST-segment elevation myocardial infarction.** *J Am Coll Cardiol* 2005, **45**:999-1002.
 38. Karlsberg RP, Cryer PE, Roberts R: **Serial plasma catecholamine response early in the course of clinical acute myocardial infarction: relation to infarct extent and mortality.** *Am Heart J* 1981, **102**:24-29.

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp

